hackint0sh/New-Dataset huggingface dataset:
This is a mechanistic study consisting of obtaining blood and skin samples from participants at baseline. Individuals may also undergo a clinically indicated oral food challenge and have blood and skin samples collected at various times during the oral food challenge. This study will create a molecular map of the pathology of atopic dermatitis and food allergy. This information will be deployed to evaluate the hypothesis that atopic dermatitis and food allergy share unique genetic transcriptional signals in which the study team can then further analyze pathological pathways and cell types. conditions: Atopic Dermatitis conditions: Food Allergy conditions: Healthy studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL primaryPurpose: BASIC_SCIENCE masking: NONE count: 200 type: ESTIMATED name: Data and biospecimen collection name: Skin biopsies name: Oral Food Challenge (OFC) procedures measure: Anaphylaxis occurrence rates in each group measure: Anaphylaxis severity in each group measure: Reaction rates in each group measure: Anaphylaxis likelihood in each group based on the Brighton score sex: ALL minimumAge: 10 Years maximumAge: 55 Years stdAges: CHILD stdAges: ADULT facility: University of Michigan status: RECRUITING city: Ann Arbor state: Michigan zip: 48109 country: United States name: Bridgette Kaul, RN role: CONTACT phone: 734-963-5634 email: bbeaupre@umich.edu name: Chase Schuler, MD role: PRINCIPAL_INVESTIGATOR lat: 42.27756 lon: -83.74088 hasResults: False
nctId: NCT06300671 id: PNSÖ-Subtalar pronation briefTitle: The Effect of Subtalar Joint Pronation Amount on Lower Extremity Alignment and Performance overallStatus: RECRUITING date: 2023-12-15 date: 2024-04-30 date: 2024-05-30 date: 2024-03-08 date: 2024-03-08 name: Bahçeşehir University class: OTHER briefSummary: The lower extremity consists of segments that can be affected by the relative position of each other. Deviation of one segment from its normal alignment in the lower extremity also affects the alignment of other segments. The hip joint can affect the frontal plane alignment from proximal to distal, while the foot and ankle complex can also affect it from distal to proximal. Increased subtalar joint pronation in the kinetic chain from distal to proximal; is associated with decreased dorsiflexion angle and increased frontal plane projection angle. It has been shown that ankle dorsiflexion limitation causes changes in the biomechanics and kinematics of landing after jumping, but no study examining the effect of foot pronation on jump tests has been found in the literature. Since the foot is located at the most distal point and acts as a support base for the kinematic chain, the smallest dynamic change in the foot affects the balance of the whole body. Due to foot pronation, changes in the sole contact surface may make it difficult for the foot to adapt to the ground, balance and postural stabilization may be adversely affected, and an increase in the workload of the muscles around the joint may be observed. In another study, it is mentioned that there is limited evidence about the effect of foot posture on postural stability. Although there are studies in the literature examining the effects of subtalar joint pronation on lower extremity alignment and postural stability, studies need to examine the effects of different subtalar joint pronation amounts on lower extremity alignment, jumping performance, and postural stability. Our study will contribute to the literature with this aspect. conditions: Balance Disorders conditions: Foot Injury conditions: Lower Extremity Problem studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL interventionModelDescription: 48 healthy individuals between the ages of 18-40 constitute the population of the study. Participants randomized into neutral, pronation, and hyperpronation groups. primaryPurpose: SCREENING masking: NONE count: 48 type: ESTIMATED name: Foot Posture Index-6 measure: Postural Stability measure: Frontal Plane Projection Angle measure: Foot and Ankle Ability Measurement measure: Navicular Drop Test measure: Weight bearing lunge test measure: Countermovement jump test without arm swing sex: ALL minimumAge: 18 Years maximumAge: 40 Years stdAges: ADULT facility: Bahcesehir University status: RECRUITING city: Besiktas state: Istanbul zip: 34353 country: Turkey name: Pelin Pişirici, PT, PhD role: CONTACT phone: 05055016076 email: pelinpisirici@gmail.com name: Ozlem Feyzioglu, PT, PhD role: CONTACT phone: 05353529794 email: fztozlemfeyzioglu@gmail.com hasResults: False
nctId: NCT06300658 id: 900/2/24 briefTitle: Stellate Ganglion Block for Preserving Arteriovenous Fistula in Hemodialysis Patients Undergoing Major Lower Limb Orthopedic Surgery overallStatus: RECRUITING date: 2024-03-09 date: 2024-09-01 date: 2024-09-01 date: 2024-03-08 date: 2024-03-12 name: Aswan University class: OTHER briefSummary: The aim of this study is to evaluate the role of stellate ganglion blockade (SGB) for preserving arteriovenous fistula in hemodialysis patients undergoing major lower limb orthopedic surgery. conditions: Stellate Ganglion Block conditions: Arteriovenous Fistula conditions: Hemodialysis conditions: Major Lower Limb Orthopedic Surgery studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 50 type: ESTIMATED name: Stellate ganglion block measure: Fistula flow rate measure: Peak systolic velocity (PSV) measure: End diastolic velocity (EDV) measure: Incidence of failure measure: Adverse effects sex: ALL minimumAge: 21 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Aswan University status: RECRUITING city: Aswan zip: 81528 country: Egypt name: Ayman M Eldemrdash, MD role: CONTACT phone: 00201001296116 email: ayman.mohamady@aswu.edu.eg name: Soudy S Hammad, MD role: SUB_INVESTIGATOR name: Tarek S Hemaida, MD role: SUB_INVESTIGATOR name: Taha T Dardeer, MD role: SUB_INVESTIGATOR name: Ahmed A Mohsen, MD role: SUB_INVESTIGATOR name: Ahmed K Fathy, MD role: SUB_INVESTIGATOR name: Gamal H Shams, MD role: SUB_INVESTIGATOR lat: 24.09082 lon: 32.89942 hasResults: False
nctId: NCT06300645 id: SPLATTvsTATT in recurrent CTEV briefTitle: SPLATT to Peroneus Brevis vs TATT to Lateral Cuneiform acronym: Recurrent CTEV overallStatus: ENROLLING_BY_INVITATION date: 2024-01-17 date: 2025-03-01 date: 2026-03-01 date: 2024-03-08 date: 2024-03-12 name: Assiut University class: OTHER briefSummary: Congenital talipes equinovarus, is a common congenital foot deformity involving hindfoot equinus and varus, along with mid-/forefoot adduction and cavus. Currently, the Ponseti method is the preferred initial treatment for idiopathic clubfoot1
The present study aims to assess the outcome of utilizing SPLATT to peroneus brevis procedure in the treatment of recurrent CTEV in comparison to the original total TATT to the lateral cuneiform conditions: Recurrent Congenital Talipes Equinovarus studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 25 type: ESTIMATED name: SPLATT measure: Correction of recurrent congenital talipes sex: ALL minimumAge: 4 Years maximumAge: 12 Years stdAges: CHILD facility: Assiut university hospital city: Assiut zip: 71515 country: Egypt lat: 27.18096 lon: 31.18368 hasResults: False
nctId: NCT06300632 id: Geriatric Locomotive Syndrome briefTitle: Geriatric Locomotive Syndrome and Related Factors in Older Adults overallStatus: RECRUITING date: 2024-04-15 date: 2024-06-01 date: 2024-07-01 date: 2024-03-08 date: 2024-04-16 name: Kırıkkale University class: OTHER briefSummary: It has been stated that the results of physical function and physical performance affecting locomotive syndrome in elderly individuals are controversial and studies are still needed. However, no studies have been found examining its relationship with the decrease in physical activity level, decline in cognitive functions, kinesiophobia (fear of movement) and fatigue seen in old age. Early detection of locomotive syndrome risk factors in elderly individuals will help prevent this condition, detect the risk of falling in elderly individuals and increase their quality of life. Based on these deficiencies, it is aimed to examine the relationship between locomotive syndrome and kinesiophobia, physical activity level, physical performance, fatigue and cognitive functions in elderly individuals. conditions: Locomotive Syndrome studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: PROSPECTIVE count: 97 type: ESTIMATED name: geriatric locomotive syndrome measure: Geriatric Locomotive Function Scale measure: Two Step Test measure: Stand Up Test measure: Tampa Kinesiophobia Scale measure: Physical Activity Scale for the Elderly (PASE) measure: Short Physical Performance Battery measure: Fatigue Severity Scale measure: Montreal Cognitive Assessment Scale (MoCA) sex: ALL minimumAge: 65 Years maximumAge: 85 Years stdAges: OLDER_ADULT facility: Ayşe Abit Kocaman status: RECRUITING city: Kırıkkale country: Turkey name: Ayşe Abit Kocaman, Asst. Prof. role: CONTACT phone: +90318-357 37 38 / 4700 email: ayseabit@gmail.com lat: 39.84528 lon: 33.50639 hasResults: False
nctId: NCT06300619 id: 2022-066 briefTitle: Pilates+4MS: Pilates Intervention for Multiple Sclerosis acronym: P+4MS overallStatus: COMPLETED date: 2022-04-05 date: 2022-08-25 date: 2022-08-25 date: 2024-03-08 date: 2024-03-08 name: University of Colorado, Colorado Springs class: OTHER name: University of Illinois at Urbana-Champaign briefSummary: The goal of this clinical trial is to test the physical health benefits of seated Pilates in the multiple sclerosis (MS) population. The main questions it aims to answer are: 1) is it feasible to deliver a seated Pilates class for 12 weeks, twice weekly over Zoom in a group format among participants with mild, moderate, and severe multiple sclerosis? 2) what are the mobility, balance, and symptom benefits of a 12-week seated Pilates class? 3) Does incorporating hip and shoulder stabilization augment the benefits compared to a standard seated Pilates protocol? 4) Are there benefits to physical activity participation? Participants will be screened over the phone for eligibility criteria and then scheduled for in-person data collection. In person data collection will involve: 1) completing the Timed 25-Foot Walk a total of 4 times, 2) the Timed Up and Go a total of 4 times, 3) the Berg Balance Scale a total of 2 times, and 4) a set of 8 questionnaires about multiple sclerosis symptoms and impact, and physical activity behavior. Participants will receive a FitBit and then will be randomized into the Pilates only group or the Pilates+4-Quadrant stability group for the intervention. The intervention is 12 weeks long, both groups meet twice weekly on Zoom for 60 minutes with 1 of 2 instructors and other class participants (12 per group). They wear the FitBit for all 12 weeks and then return for testing to repeat testing items 1-4 above. Researchers will compare the functional outcomes between the Pilates only group and the Pilates+4-Quadrant Stability group to see if there are differences in mobility, balance and physical activity outcomes. conditions: Multiple Sclerosis studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: OTHER masking: SINGLE maskingDescription: Participants know that there are 2 Pilates groups, but not which group is under investigation vs. the comparison group. whoMasked: PARTICIPANT count: 22 type: ACTUAL name: Pilates+4 name: Pilates measure: Timed 25 Foot Walk measure: Timed Up and Go measure: Berg Balance Scale measure: Triaxial Accelerometer (FitBit) Physical Activity Data (minutes of wear time in sedentary time and light, moderate and vigorous physical activity) measure: The Godin-Shepherd Leisure Time Exercise Questionnaire measure: Late-Life Function and Disability Instrument Short Form measure: Leeds Multiple Sclerosis Quality of Life Scale measure: Modified Fatigue Impact Scale measure: Multiple Sclerosis Impact Scale sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Hybl Sports Medicine and Performance Center city: Colorado Springs state: Colorado zip: 80918 country: United States lat: 38.83388 lon: -104.82136 hasResults: False
nctId: NCT06300606 id: NOL1 and RA briefTitle: Nociception Index Level (NOL) Perioperative Monitoring During Regional Anesthesia acronym: NOL and LRA overallStatus: RECRUITING date: 2024-03-05 date: 2024-04-15 date: 2024-04-15 date: 2024-03-08 date: 2024-03-08 name: American Hospital of Paris class: OTHER name: Nataliya KARASHCHUK name: Briana LUI name: Thierry GUENOUN name: Stephane ROMANO briefSummary: This prospective observational study was conducted to assess pain using NOL index under locoregional anesthesia for orthopedic surgery of the upper limb. We included 50 consecutive adult patients scheduled for orthopedic surgery of the upper limb under locoregional anesthesia. The locoregional anesthesia was performed under ultrasound, with or without neurostimulation. Intraoperative pain is assessed using NOL index monitoring, ALGISCORE and Numerical Scale, and second point study is the midazolam and propofol requirement. conditions: Regional Anesthesia conditions: Pain conditions: Intraoperative Monitoring studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 25 type: ESTIMATED name: NOL monitoring measure: pain score measure: pain score measure: sedative requirement measure: anxiolytic requirement measure: failure of regional anesthesia sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Gilles BOCCARA status: RECRUITING city: Neuilly-sur-Seine zip: 92200 country: France name: Gilles BOCCARA role: CONTACT phone: +33662382833 email: gilles.boccara@ahparis.org name: thierry GUENOUN role: CONTACT phone: +33146412691 email: thierry.guenoun@ahparis.org lat: 48.8846 lon: 2.26965 hasResults: False
nctId: NCT06300580 id: M23-991 briefTitle: Study of Oral ABBV-932 Capsules to Evaluate Dopamine D2 and D3 Receptor Occupancy in Brain in Adult Healthy Volunteers overallStatus: NOT_YET_RECRUITING date: 2024-05-03 date: 2024-10-30 date: 2024-10-30 date: 2024-03-08 date: 2024-04-04 name: AbbVie class: INDUSTRY briefSummary: The main objective of this study is to evaluate the dopamine D2 and D3 receptor occupancy in the brain as measured by PET with radiotracer \[11C\]-(+)-PHNO up to 14 days of once-daily oral doses of ABBV-932 in healthy subjects.
Participants will be confined for approximately 15 days. Participants will receive 3 \[11C\]-(+)-PHNO PET scans during the study. Adverse Events and blood tests will be performed. conditions: Healthy Volunteers studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: BASIC_SCIENCE masking: NONE count: 12 type: ESTIMATED name: ABBV-932 measure: Change in Dopamine Receptor Occupancy in Brain Measured by Positron Emission Tomography (PET) measure: Number of Participants with Adverse Events (AEs) sex: ALL minimumAge: 23 Years maximumAge: 55 Years stdAges: ADULT hasResults: False
nctId: NCT06300567 id: CFTR-RD misdiagnosis briefTitle: Assessment of Patients Not Concluded After Neonatal Screening of Cystic Fibrosis. overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2026-05-02 date: 2026-11-02 date: 2024-03-08 date: 2024-03-12 name: Hôpital Necker-Enfants Malades class: OTHER briefSummary: Assessment of the outcome of patients not concluded fir cystic fibrosis, either symptomatic patients or asymptomatic children detected by newborn screening for cystic fibrosis. The aim is to identify patients potentially at risk of progressing to the clinical spectrum of cystic fibrosis conditions: CFTR-RD studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 400 type: ESTIMATED name: data collection measure: lung Imaging measure: lung infection measure: pancreatic function sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06300554 id: 2023-1653 id: A171600 type: OTHER domain: UW Madison id: Version 1/26/2024 type: OTHER domain: UW Madison briefTitle: 10th Mountain Healthy Minds Program App Study overallStatus: NOT_YET_RECRUITING date: 2024-06 date: 2024-06 date: 2024-06 date: 2024-03-08 date: 2024-04-25 name: University of Wisconsin, Madison class: OTHER briefSummary: The purpose of the study is to evaluate the acceptability, feasibility, and preliminary effects of the Healthy Minds Program (HMP) App in approximately 150 active duty military members. conditions: Well-Being, Psychological studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 150 type: ESTIMATED name: Healthy Minds Program App measure: System Usability Scale Score measure: Acceptability of Intervention Measure (AIM) measure: Intervention Appropriateness Measure (IAM) measure: Feasibility of Intervention Measure (FIM) measure: HMP App Usage: Did you use the Healthy Minds Program App (Yes or No) measure: HMP App Usage: Did you download the Healthy Minds Program App (Yes or No) measure: Change in Perceived Stress Score measure: Change in WHO-5 Well-Being Score measure: Change in PROMIS Depression Score measure: Change in PROMIS Anxiety Score measure: Change in Meaning of Life Questionnaire - Presence Subscale Score measure: Change in NIH Toolbox Loneliness Score measure: Change in Suicide Cognitions Scale Score measure: HMP App Usage: How many times did you use the HMP App measure: HMP App Usage: Reasons for not downloading the HMP App measure: HMP App Usage: Reasons for not opening the HMP App sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Wisconsin city: Madison state: Wisconsin zip: 53705 country: United States lat: 43.07305 lon: -89.40123 hasResults: False
nctId: NCT06300541 id: 940730 briefTitle: Prevalence and Impact of Sarcopenia in Patients With Inflammatory Bowel Disease overallStatus: RECRUITING date: 2021-04-01 date: 2027-05-01 date: 2027-12-01 date: 2024-03-08 date: 2024-03-08 name: Sahlgrenska University Hospital, Sweden class: OTHER name: Ersta Hospital, Sweden briefSummary: Sarcopenia is a condition characterized by significant muscle loss resulting in impaired muscle function. This condition is likely associated with a biological deviation leading to reduced reserves to withstand stressors, resulting in a poorer prognosis. The incidence of sarcopenia among patients with inflammatory bowel diseases (Ulcerative Colitis and Crohn's disease) is currently approximately 40-60%. This is likely a consequence of the preference for drug treatment over surgery, while many patients have continuous inflammation in their intestines leading to muscle loss and subsequently increased morbidity and mortality.
The participants are longitudinally monitored with measurements taken at the flare-up/before surgery and one year afterward, including body composition, function, dietary recording, quality of life, blood tests, fecal samples, and intestinal biopsies that will be analyzed. The investigators plan to correlate body composition with a biological profile and then evaluate if there is an association. Additionally, the investigators aim to analyze if these markers are linked to different outcomes after colectomy. This study will contribute to an enhanced understanding of patients with advanced IBD and possibly change the perspective on how the clinicians should prioritize these patients for surgery. The investigators believe this study will lead to an improvement in healthcare quality and an enhanced understanding of how these disease processes function. conditions: Inflammatory Bowel Diseases conditions: Sarcopenia studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 180 type: ESTIMATED name: Colectomy measure: Number of participants with increase in muscle mass as assessed by DEXA scan. sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Sahlgrenska University Hospital status: RECRUITING city: Gothenburg zip: 41345 country: Sweden name: Jonas Varkey, MD, PhD role: CONTACT phone: 0046764030388 email: jonas.varkey@vgregion.se lat: 57.70716 lon: 11.96679 hasResults: False
nctId: NCT06300528 id: OSU-23423 id: NCI-2024-01530 type: REGISTRY domain: CTRP (Clinical Trial Reporting Program) briefTitle: Pemigatinib for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma or Marginal Zone Lymphoma overallStatus: NOT_YET_RECRUITING date: 2024-04-30 date: 2025-12-31 date: 2025-12-31 date: 2024-03-08 date: 2024-03-08 name: Narendranath Epperla class: OTHER briefSummary: This phase II trial tests how well pemigatinib works in treating patients with mantle cell lymphoma (MCL) or marginal zone lymphoma (MZL) that has come back after a period of improvement (relapsed) or that does not respond to treatment (refractory). Pemigatinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. conditions: Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue conditions: Recurrent Mantle Cell Lymphoma conditions: Recurrent Marginal Zone Lymphoma conditions: Recurrent Nodal Marginal Zone Lymphoma conditions: Recurrent Splenic Marginal Zone Lymphoma conditions: Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue conditions: Refractory Mantle Cell Lymphoma conditions: Refractory Marginal Zone Lymphoma conditions: Refractory Nodal Marginal Zone Lymphoma conditions: Refractory Splenic Marginal Zone Lymphoma studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 25 type: ESTIMATED name: Biospecimen Collection name: Bone Marrow Aspiration name: Bone Marrow Biopsy name: Computed Tomography name: Pemigatinib name: Positron Emission Tomography measure: Overall response rate (ORR) measure: Complete response (CR) rate measure: Duration of response (DOR) measure: Progression-free survival (PFS) measure: Overall survival (OS) measure: Incidence of adverse events (AEs) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Ohio State University Comprehensive Cancer Center city: Columbus state: Ohio zip: 43210 country: United States name: Narendranath Epperla, MD, MS role: CONTACT phone: 614-393-3196 name: Narendranath Epperla, MD, MS role: PRINCIPAL_INVESTIGATOR lat: 39.96118 lon: -82.99879 hasResults: False
nctId: NCT06300502 id: 2023P003620 briefTitle: Assessing the Efficacy of Repeat, Monthly Treatments of Cutaneous Neurofibromas (cNFs) overallStatus: NOT_YET_RECRUITING date: 2024-06 date: 2025-12 date: 2025-12 date: 2024-03-08 date: 2024-03-08 name: Massachusetts General Hospital class: OTHER name: Johns Hopkins University briefSummary: This study will evaluate the tolerability and effectiveness of four FDA-approved treatments in Neurofibromatosis Type 1 Cutaneous Neurofibromas. These treatments are: a 1064nm laser, a 755nm laser, and Kybella and Polidocanol injections. Each patient will have a treatment and a control site.